

**GOVERNMENT OF NAGALAND
NAGALAND HEALTH PROTECTION SOCIETY
DEPARTMENT OF HEALTH & FAMILY WELFARE
NAGALAND :: KOHIMA**

No. NHPS/13-354/2025/2053

Dated Kohima the ^{1st} July 2025

OFFICE MEMORANDUM

Sub: Guidelines for Coverage of Immunotherapy Drug Injection Toripalimab at Discounted Rate under CMHIS (EP)

In continuation of the commitment to provide financial protection for serious illnesses under the Chief Minister Health Insurance Scheme for Employees and Pensioners (CMHIS-EP) and to promote sustainability of the Scheme, the Department has entered into an MoU with Dr. Reddy's Laboratories Ltd, Survey No 47, Bachupally Village, Bachupally Mandal, Hyderabad- 500090 to provide Zytorvi (Toripalimab) Injection at a discounted rate to the beneficiaries of CMHIS-EP subject to fulfilment of the terms and conditions of the permission granted by Central Licensing Authority to Dr. Reddy's Laboratories Ltd for Import & sale or distribution of Toripalimab Injection 240 mg/ 6ml (r-DNA origin) vide Permission No. IMP/BIO/24/000049 dated 10th May 2024.

Based on the recommendation of the State Medical Committee, the following guidelines are hereby issued for the coverage and administration of the immunotherapy drug injection Toripalimab for Nasopharyngeal Cancer (NPC):

1. Eligibility Criteria:

Coverage of Inj. Toripalimab under CMHIS (EP) shall be extended only to those beneficiaries who meet the following conditions:

- a. Must be a registered and active beneficiary under CMHIS (EP) during the policy period with a CMHIS(EP) Card.
- b. Treatment must be prescribed by a qualified Oncologist in empanelled hospitals only, supported by documented clinical justification
- c. Coverage will be subject to the overall immunotherapy cap of ₹10,00,000 per household per policy period, as defined under CMHIS (EP).

2. Indications for Clinical Use as per Central Licensing Authority:

- a. Zytorvi (Toripalimab) is indicated, in combination with cisplatin and gemcitabine, for first line treatment of adults with metastatic or with recurrent, locally advanced Nasopharyngeal Cancer (NPC).
- b. Zytorvi (Toripalimab) is indicated, as a single agent, for the treatment of adult with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

NB: Dr. Reddy's Laboratories Ltd will provide training to the Clinicians. All concerned EHCPs are to contact the firm for Capacity Building, if required.

3. Drug Coverage Details

The following terms shall govern the pricing and reimbursement of Inj. Toripalimab:

- a. Drug Name: Toripalimab 240 mg/ 6ml (Immunotherapy)
- b. Rate under CMHIS (EP):
Up to five (5) units per eligible beneficiary (Patient) under the Scheme shall be covered @ ₹93,750 + GST per unit. Additional units exceeding 5 units shall be covered at a concessional rate of ₹1,000 per unit + GST and shall be availed by beneficiaries by registering on toll free number 1800 202 1636.

Note 1. All immunotherapy—including Injection Toripalimab (240 mg @ ₹93,750 + GST per unit)—shall be reimbursed by CMHIS-EP in full, subject to a cumulative cost ceiling of ₹10,00,000 per household per policy period.

Note 2. Beneficiaries shall not be asked to bear any portion of the cost for Toripalimab so long as the aggregate immunotherapy expenses remain within the ₹10 lakh cap. However, in case the overall immunotherapy cap of ₹10,00,000 per household per policy period is exceeded, beneficiary shall bear the cost at the rate as specified above.

Claim Processing and Adjudication

- a. All claims for Inj. Toripalimab must be submitted under the "Targeted Therapy" package via the TMS. Empanelled hospitals shall ensure accurate documentation of unit doses and cumulative costs to facilitate timely adjudication.
- b. The Insurer shall ensure timely and transparent adjudication of these claims within the prescribed TurnAround Time (TAT).

5. Operational Instructions

- a. All empanelled hospitals under CMHIS (EP) are directed to adhere strictly to these guidelines and facilitate uninterrupted availability and administration of Inj. Toripalimab to eligible beneficiaries.
- b. Hospitals must ensure informed consent from beneficiaries, especially in cases where co-payment for additional units is applicable.
- c. Beneficiaries must be registered at Toll-Free Number: 1800 202 1636 after the drug is prescribed by the clinician to avail the treatment under CMHIS.
- d. Coordination for procurement and clarification of supply chain-related matters shall be addressed through the contacts listed below.

6. Contact for Coordination and Support

For support related to claims, drug procurement, or beneficiary queries, the following contacts may be reached:

- a. Toll-Free Number: 1800 202 1636
- b. Mr. Deep Cheetri: +91 97060 80183
- c. Mr. Shubhayan Das: +91 90070 36640

This Office Memorandum shall come into immediate effect and remain in force until further orders. Non-compliance by empanelled hospitals or claim processing delays by the Insurer shall be viewed seriously.



(THAVASEELAN K) IAS
CEO, Nagaland Health Protection Society

No. NHPS/13-354/2025/

Dated Kohima theJuly 2025

Copy to:

1. The Commissioner and Secretary to the Government of Nagaland, Health and Family Welfare Department, for kind information.
2. The Principal Director, Directorate of Health & Family Welfare, Nagaland, for kind information.
3. The Deputy Commissioner & Chairman of District Implementation Unit of all Districts, Nagaland for kind information.
4. The Chief Medical Officer of all Districts, Nagaland for kind information & necessary action.
5. All EHCPs for kind information & necessary action.
6. RGICL, for kind information & necessary action.
7. Office Copy


(THAVASEELAN K) IAS
CEO, Nagaland Health Protection Society